AOD-9604: A Precisely Engineered Fragment That Missed Its Human Endpoint

The short version

AOD-9604 is a small, synthetic fragment — just 16 amino acids — modeled on the tail end of human growth hormone (GH), the part researchers believed was responsible for GH's fat-burning effect without its growth-promoting or blood-sugar-raising effects. The idea was to keep the useful piece and drop the rest.

In animal studies, that idea largely held up: the fragment reduced fat and increased fat-burning activity in obese mice ^[4][5], and safety testing in rats and primates raised no red flags ^[2]. Roughly 900 people took part in the human trial program that followed, and the compound was well tolerated — its side-effect profile was hard to distinguish from placebo ^[3].

The honest headline, though, is that the pivotal human obesity trial did not show statistically significant weight loss beyond placebo, and the drug's development as an obesity treatment was discontinued. This page describes what was studied and what wasn't. No dose is recommended for any use.

What it is

AOD-9604 — sometimes written AOD9604, or by its more technical name, the tyrosine-substituted human growth hormone fragment 176-191 — is a synthetic hexadecapeptide (16 amino acids) built to reproduce the C-terminal 'tail' domain of human growth hormone. The natural GH sequence at that position has phenylalanine at the front; AOD-9604 substitutes a tyrosine in its place, hence the name. Two cysteines form an internal disulfide bridge, mirroring a structural loop found in the parent hormone.

The reported sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. It is not human growth hormone itself, and it does not bind the growth hormone receptor — that distinction is the entire premise behind isolating this fragment in the first place.

How it works

Intact human growth hormone drives fat metabolism, but it also promotes tissue growth and raises IGF-1 and blood glucose — effects that make chronic GH use unattractive as a weight-loss strategy for people without a GH deficiency. AOD-9604 was engineered to keep only the fat-metabolizing piece.

Mechanistically, it appears to work in two connected ways: it inhibits acetyl-CoA carboxylase, an enzyme the body uses to build new fat (a process called lipogenesis), and it up-regulates beta-3 adrenergic receptors in white adipose tissue, a receptor family strongly tied to fat-burning (lipolysis) and energy expenditure ^[4]. In obese mice lacking a functional beta-3 adrenergic receptor, the chronic weight- and fat-lowering effect of both GH and AOD-9604 disappeared entirely, even though the acute fat-oxidation boost from either compound persisted ^[4]. That single knockout experiment is one of the clearer pieces of evidence for how — and how much — the fragment actually depends on that receptor pathway.

What the research shows

Rodent fat metabolism. Two related mouse studies from the same research group found that chronic treatment with either intact human GH or AOD-9604 reduced body weight and fat and increased fat oxidation in obese mice, with beta-3 adrenergic receptor expression identified as a likely driver ^[4][5].

Non-clinical safety. Toxicology work in rats and primates found no genotoxic or other safety concerns after chronic administration, and identified a very short half-life — roughly three minutes after intravenous injection — with the compound degrading through sequential removal of amino acids from its N-terminus. Oral absorption was also demonstrated in this body of work ^[2].

Human trial program. Across roughly six clinical trials and about 900 obese human subjects, oral AOD9604 at daily doses from 0.25 mg up to 54 mg, over periods from 7 days to 24 weeks, produced a safety and tolerability profile essentially indistinguishable from placebo — importantly, without the adverse effects associated with full-length growth hormone ^[3].

Osteoarthritis, a separate line of inquiry. In a rabbit model of collagenase-induced knee osteoarthritis, weekly intra-articular AOD9604 injections — with or without hyaluronic acid — reduced cartilage-degeneration scores compared with saline over 4-7 weeks ^[1]. This is preclinical, joint-specific research, unrelated to the obesity program, and it has not been followed by published human osteoarthritis trials of AOD-9604.

Reported effects, cautions & safety

In peptide and biohacker forums, people describe a fairly mild day-to-day experience with AOD-9604 — anecdotal, not clinical evidence, and none of it a substitute for the trial record above. The most consistent theme is tolerability: users report few complaints, echoing the published finding that side effects were hard to distinguish from placebo. People who have also tried growth hormone or GH secretagogues frequently note the absence of the water retention, facial puffiness, and tingling they associate with raising IGF-1. A subset describe a mild lift in energy, and some report eating a little less, though both are just as easily explained by concurrent diet changes as by the peptide itself. Community claims of 'spot' or localized fat loss near the injection site are common but biologically implausible — no trial supports fat loss by injection location.

The more consistent theme, however, is disappointment — anecdotal, not clinical evidence, but notably aligned with the trial outcome itself ^[3]. The most frequently repeated report across these communities is simply that people do not see meaningful body-fat reduction, which tracks with the human obesity trials failing to beat placebo. Occasional injection-site redness or irritation is reported, generally described as a routine reaction to subcutaneous injection rather than a drug-specific effect. Unlike growth hormone, users do not generally report changes in strength, recovery, or muscle — consistent with AOD-9604 not engaging the growth hormone receptor at all. Experienced users also flag a practical concern: gray-market 'research' vials vary widely in purity and identity, so any reported effect, or lack of one, may reflect the actual vial contents as much as the molecule.

Cited cautions from the clinical literature:

• Investigational, not approved for any indication. AOD-9604 was developed as an oral anti-obesity candidate but never gained marketing approval anywhere; there is no approved dose, indication, or manufacturing standard for it, and current compounding status should be independently verified.
• Human weight-loss efficacy was not demonstrated. Despite the encouraging rodent data above, the trial program of roughly 900 obese subjects did not show statistically significant weight loss versus placebo, and the obesity development program was discontinued ^[3].
• The fat-metabolism mechanism is largely preclinical. Acetyl-CoA carboxylase inhibition and beta-3 adrenergic receptor up-regulation were characterized chiefly in mouse and cell models; this mechanistic story has not translated into a demonstrated human fat-loss effect ^[4][5].
• Long-term human safety data are limited. The published human exposure tops out around 24 weeks; there is no long-term surveillance beyond that window ^[3].
• WADA prohibition. As a growth-hormone fragment, AOD-9604 falls under the WADA Prohibited List (Section S2) and is prohibited at all times in competitive sport.

Where it fits in Metabolic & Weight Research

AOD-9604 is the caution on this desk — proof that a clean mechanistic story and reassuring animal data do not guarantee a human result. Where tesamorelin earned an approval by demonstrating a specific, measurable effect (visceral-fat reduction) in a specific population, and tirzepatide demonstrated broad, large-magnitude weight loss across large trials, AOD-9604's obesity program produced a negative pivotal result and was shelved. Its value here is instructive rather than practical: a reminder that rodent efficacy, favorable safety, and a tidy mechanism are necessary but not sufficient. See the comparison page for how the three stack up side by side.